The importance of detecting cytomegalovirus infections in studies evaluating new therapies for severe sepsis

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Cytomegalovirus infection is present in the majority of the population and is associated with substantial morbidity and mortality in immunocompromised patients. Recently, this viral infection has also been reported in nonimmunocompromised critically ill patients. We hypothesize that active cytomegalovirus infection may confound survival outcomes in severe sepsis trials. Scenarios based on three published studies on activated protein C were used as real examples for statistical simulations looking for how much bias in favor of or against activated protein C would be observed in single-arm studies (scenario 1), phase II trials (scenario 2A/2B), and phase III trials (scenario 3A/3B). Scenario 1 simulations evaluated a single-arm study and demonstrated that confounding biases could cause an absolute decrease of 5.7% to an increase of 6.1% on mortality rates of similar studies. Scenarios 2A and 3A evaluated phase II and III trials assuming that activated protein C is truly effective; they showed that trials with an imbalance on the proportion of active cytomegalovirus infection between study arms could lead to false-negative rates (p errors) in up to 25% of phase II trials and up to 42% of phase III trials. Scenarios 2B and 3B assumed that activated protein C was truly ineffective; they showed that imbalanced cytomegalovirus infection between arms would cause false-positive rates (a errors) in up to 5% of phase II and up to 7% of all phase III trials. The inclusion of an imbalanced proportion of patients with active cytomegalovirus infection may severely compromise the reliability of outcome results of severe sepsis trials independent of their design. Even randomized trials could have a much higher probability of false-negative rates for a new therapy than designed. Future severe sepsis trials should consider including active cytomegalovirus infection as a prospective covariate.

Original languageEnglish (US)
Pages (from-to)S663-S667
JournalCritical care medicine
Volume38
Issue number10 SUPPL.
DOIs
StatePublished - Oct 2010

Fingerprint

Cytomegalovirus Infections
Sepsis
Protein C
Therapeutics
Mortality
Immunocompromised Host
Virus Diseases
Critical Illness
Reproducibility of Results
Morbidity
Survival
Population

Keywords

  • Cytomegalovirus
  • Immunocom-promised
  • Sepsis
  • Survival outcome
  • Trial design

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

The importance of detecting cytomegalovirus infections in studies evaluating new therapies for severe sepsis. / Kalil, Andre C; Sun, Junfeng; Florescu, Diana F.

In: Critical care medicine, Vol. 38, No. 10 SUPPL., 10.2010, p. S663-S667.

Research output: Contribution to journalArticle

@article{21a65ac0c31c4c99b2020086937a08ef,
title = "The importance of detecting cytomegalovirus infections in studies evaluating new therapies for severe sepsis",
abstract = "Cytomegalovirus infection is present in the majority of the population and is associated with substantial morbidity and mortality in immunocompromised patients. Recently, this viral infection has also been reported in nonimmunocompromised critically ill patients. We hypothesize that active cytomegalovirus infection may confound survival outcomes in severe sepsis trials. Scenarios based on three published studies on activated protein C were used as real examples for statistical simulations looking for how much bias in favor of or against activated protein C would be observed in single-arm studies (scenario 1), phase II trials (scenario 2A/2B), and phase III trials (scenario 3A/3B). Scenario 1 simulations evaluated a single-arm study and demonstrated that confounding biases could cause an absolute decrease of 5.7{\%} to an increase of 6.1{\%} on mortality rates of similar studies. Scenarios 2A and 3A evaluated phase II and III trials assuming that activated protein C is truly effective; they showed that trials with an imbalance on the proportion of active cytomegalovirus infection between study arms could lead to false-negative rates (p errors) in up to 25{\%} of phase II trials and up to 42{\%} of phase III trials. Scenarios 2B and 3B assumed that activated protein C was truly ineffective; they showed that imbalanced cytomegalovirus infection between arms would cause false-positive rates (a errors) in up to 5{\%} of phase II and up to 7{\%} of all phase III trials. The inclusion of an imbalanced proportion of patients with active cytomegalovirus infection may severely compromise the reliability of outcome results of severe sepsis trials independent of their design. Even randomized trials could have a much higher probability of false-negative rates for a new therapy than designed. Future severe sepsis trials should consider including active cytomegalovirus infection as a prospective covariate.",
keywords = "Cytomegalovirus, Immunocom-promised, Sepsis, Survival outcome, Trial design",
author = "Kalil, {Andre C} and Junfeng Sun and Florescu, {Diana F}",
year = "2010",
month = "10",
doi = "10.1097/CCM.0b013e3181f20319",
language = "English (US)",
volume = "38",
pages = "S663--S667",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "10 SUPPL.",

}

TY - JOUR

T1 - The importance of detecting cytomegalovirus infections in studies evaluating new therapies for severe sepsis

AU - Kalil, Andre C

AU - Sun, Junfeng

AU - Florescu, Diana F

PY - 2010/10

Y1 - 2010/10

N2 - Cytomegalovirus infection is present in the majority of the population and is associated with substantial morbidity and mortality in immunocompromised patients. Recently, this viral infection has also been reported in nonimmunocompromised critically ill patients. We hypothesize that active cytomegalovirus infection may confound survival outcomes in severe sepsis trials. Scenarios based on three published studies on activated protein C were used as real examples for statistical simulations looking for how much bias in favor of or against activated protein C would be observed in single-arm studies (scenario 1), phase II trials (scenario 2A/2B), and phase III trials (scenario 3A/3B). Scenario 1 simulations evaluated a single-arm study and demonstrated that confounding biases could cause an absolute decrease of 5.7% to an increase of 6.1% on mortality rates of similar studies. Scenarios 2A and 3A evaluated phase II and III trials assuming that activated protein C is truly effective; they showed that trials with an imbalance on the proportion of active cytomegalovirus infection between study arms could lead to false-negative rates (p errors) in up to 25% of phase II trials and up to 42% of phase III trials. Scenarios 2B and 3B assumed that activated protein C was truly ineffective; they showed that imbalanced cytomegalovirus infection between arms would cause false-positive rates (a errors) in up to 5% of phase II and up to 7% of all phase III trials. The inclusion of an imbalanced proportion of patients with active cytomegalovirus infection may severely compromise the reliability of outcome results of severe sepsis trials independent of their design. Even randomized trials could have a much higher probability of false-negative rates for a new therapy than designed. Future severe sepsis trials should consider including active cytomegalovirus infection as a prospective covariate.

AB - Cytomegalovirus infection is present in the majority of the population and is associated with substantial morbidity and mortality in immunocompromised patients. Recently, this viral infection has also been reported in nonimmunocompromised critically ill patients. We hypothesize that active cytomegalovirus infection may confound survival outcomes in severe sepsis trials. Scenarios based on three published studies on activated protein C were used as real examples for statistical simulations looking for how much bias in favor of or against activated protein C would be observed in single-arm studies (scenario 1), phase II trials (scenario 2A/2B), and phase III trials (scenario 3A/3B). Scenario 1 simulations evaluated a single-arm study and demonstrated that confounding biases could cause an absolute decrease of 5.7% to an increase of 6.1% on mortality rates of similar studies. Scenarios 2A and 3A evaluated phase II and III trials assuming that activated protein C is truly effective; they showed that trials with an imbalance on the proportion of active cytomegalovirus infection between study arms could lead to false-negative rates (p errors) in up to 25% of phase II trials and up to 42% of phase III trials. Scenarios 2B and 3B assumed that activated protein C was truly ineffective; they showed that imbalanced cytomegalovirus infection between arms would cause false-positive rates (a errors) in up to 5% of phase II and up to 7% of all phase III trials. The inclusion of an imbalanced proportion of patients with active cytomegalovirus infection may severely compromise the reliability of outcome results of severe sepsis trials independent of their design. Even randomized trials could have a much higher probability of false-negative rates for a new therapy than designed. Future severe sepsis trials should consider including active cytomegalovirus infection as a prospective covariate.

KW - Cytomegalovirus

KW - Immunocom-promised

KW - Sepsis

KW - Survival outcome

KW - Trial design

UR - http://www.scopus.com/inward/record.url?scp=78650405516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650405516&partnerID=8YFLogxK

U2 - 10.1097/CCM.0b013e3181f20319

DO - 10.1097/CCM.0b013e3181f20319

M3 - Article

C2 - 21164412

AN - SCOPUS:78650405516

VL - 38

SP - S663-S667

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 10 SUPPL.

ER -